Chiara Pidone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chiara Pidone has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Anna Severino
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy
3 shared publicationsFilippo Crea
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy
3 shared publicationsFrancesco Canonico
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy
3 shared publicationsMattia Galli
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy
3 shared publicationsAlessandra Arcudi
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy
2 shared publicationsAlice Bonanni
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy
2 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5806
Standardizing Vegetation Size Measurement in Native Left-Sided Infective Endocarditis Using Artificial Intelligence
Background/Objectives: Vegetation length is a guideline-endorsed criterion for surgery in left-sided infective endocarditis (LSIE). However, its measurement is highly variable with crucial implications for decision making. A standardized measurement system would not only facilitate decision making in these patients, but also cutoff-point optimization for improving clinical guidelines. For this purpose, this work introduces an Artificial Intelligence (AI)-based system capable of extracting vegetation length from standard transesophageal echocardiography (TEE). Methods: Five echocardiographers independently measured the vegetation length of 76 vegetations from 67 consecutive patients with LSIE using offline TEE images. The AI-based system was trained on a multicenter registry with 353 patients with LSIE, comprising 282,096 echocardiographic frames annotated by an independent expert. This system was applied to measure vegetation length as an independent observer. The variability and correlation between operators and the system were assessed. Results: Lin’s concordance correlation coefficient between the AI-based system and the mean of the measurements obtained by the echocardiographers was 0.74, comparable to the coefficient obtained between the echocardiographers themselves. Bland–Altman analysis showed a mean difference of −1.0 mm between the AI-based system and the mean of the measurements obtained by the echocardiographers. Conclusions: The AI-based system for vegetation measurement demonstrates a high level of correlation and agreement with experts, similar to the concordance between human operators themselves. This level of agreement suggests that the method has the potential to reduce inter-operator variability in the measurement process. Whether AI-based vegetation size improves embolism prediction has to be further investigated.
- 24 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5806
Open AccessStandardizing Vegetation Size Measurement in Native Left-Sided Infective Endocarditis Using Artificial Intelligence
Background/Objectives: Vegetation length is a guideline-endorsed criterion for surgery in left-sided infective endocarditis (LSIE). However, its measurement is highly variable with crucial implications for decision making. A standardized measurement system would not only facilitate decision making in these patients, but also cutoff-point optimization for improving clinical guidelines. For this purpose, this work introduces an Artificial Intelligence (AI)-based system capable of extracting vegetation length from standard transesophageal echocardiography (TEE). Methods: Five echocardiographers independently measured the vegetation length of 76 vegetations from 67 consecutive patients with LSIE using offline TEE images. The AI-based system was trained on a multicenter registry with 353 patients with LSIE, comprising 282,096 echocardiographic frames annotated by an independent expert. This system was applied to measure vegetation length as an independent observer. The variability and correlation between operators and the system were assessed. Results: Lin’s concordance correlation coefficient between the AI-based system and the mean of the measurements obtained by the echocardiographers was 0.74, comparable to the coefficient obtained between the echocardiographers themselves. Bland–Altman analysis showed a mean difference of −1.0 mm between the AI-based system and the mean of the measurements obtained by the echocardiographers. Conclusions: The AI-based system for vegetation measurement demonstrates a high level of correlation and agreement with experts, similar to the concordance between human operators themselves. This level of agreement suggests that the method has the potential to reduce inter-operator variability in the measurement process. Whether AI-based vegetation size improves embolism prediction has to be further investigated.
- Open Access
- 30 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9550
Regulation of Monocyte Perilipin-2 Expression in Acute and Chronic Coronary Syndromes: Pathogenetic Implications
PLIN2 is involved in the lipid metabolism of macrophages resident in atherosclerotic plaques, and its upregulation leads to lipid droplets (LDs) accumulation. LDs enlargement results in the macrophage transformation into foam cells, a key step for the onset of atherosclerosis. In the present study, we investigated the role of PLIN2 and its regulation mechanisms in atherosclerosis and plaque instability in patients with a diagnosis of ST-elevation myocardial infarction (STEMI) and chronic coronary syndrome (CCS). We enrolled STEMI (n = 122) and CCS patients (n = 45). Peripheral blood mononuclear cells were isolated from whole blood samples. The PLIN2 protein level was analyzed in CD14+ monocytes by flow cytometry. Lipidomic panel and proteasome activity were evaluated. PLIN2 protein expression was significantly correlated with the age of CAD patients. We found no significant difference in monocyte lipid content between the two patient groups. The PLIN2 increased in STEMI as compared to CCS patients (p < 0.001). The proteasome activity being higher in STEMI as compared to CCS patients (p < 0.001), significant inverse correlations were evident between PLIN2 levels and proteasome activity in the CCS groups (p = 0.02). PLIN2 expression was higher in STEMI as compared to CCS patients, suggesting an involvement in plaque instability. Despite the proteasome activity being higher in STEMI patients, probably due to the elevated inflammatory burden, PLIN2 could escape proteasome degradation in a more efficient manner in STEMI as compared to CCS patients.
- 30 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9550
Open AccessRegulation of Monocyte Perilipin-2 Expression in Acute and Chronic Coronary Syndromes: Pathogenetic Implications
PLIN2 is involved in the lipid metabolism of macrophages resident in atherosclerotic plaques, and its upregulation leads to lipid droplets (LDs) accumulation. LDs enlargement results in the macrophage transformation into foam cells, a key step for the onset of atherosclerosis. In the present study, we investigated the role of PLIN2 and its regulation mechanisms in atherosclerosis and plaque instability in patients with a diagnosis of ST-elevation myocardial infarction (STEMI) and chronic coronary syndrome (CCS). We enrolled STEMI (n = 122) and CCS patients (n = 45). Peripheral blood mononuclear cells were isolated from whole blood samples. The PLIN2 protein level was analyzed in CD14+ monocytes by flow cytometry. Lipidomic panel and proteasome activity were evaluated. PLIN2 protein expression was significantly correlated with the age of CAD patients. We found no significant difference in monocyte lipid content between the two patient groups. The PLIN2 increased in STEMI as compared to CCS patients (p < 0.001). The proteasome activity being higher in STEMI as compared to CCS patients (p < 0.001), significant inverse correlations were evident between PLIN2 levels and proteasome activity in the CCS groups (p = 0.02). PLIN2 expression was higher in STEMI as compared to CCS patients, suggesting an involvement in plaque instability. Despite the proteasome activity being higher in STEMI patients, probably due to the elevated inflammatory burden, PLIN2 could escape proteasome degradation in a more efficient manner in STEMI as compared to CCS patients.
- Open Access
- 26 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1320
A New Frontier for Drug-Coated Balloons: Treatment of “De Novo” Stenosis in Large Vessel Coronary Artery Disease
Background: Drug-coated balloons (DCB) are a well-established option for treating in-stent restenosis endorsed by European Guidelines on myocardial revascularization. However, in recent years, a strategy of “leaving nothing behind” with DCB in de novo coronary stenosis has emerged as an appealing approach. Methods: We performed a systematic review to evaluate the current literature on the use of drug-coated balloons in the treatment of de novo stenosis in large vessel disease. Results: Observational studies, as well as randomized studies, demonstrated the safety of DCB percutaneous coronary interventions (PCI) in large vessel disease. The rate of major adverse cardiac events is even lower compared to drug-eluting stents in stable coronary artery disease. Conclusions: DCB PCI is feasible in large vessel disease, and future large, randomized studies are ongoing to confirm these results.
- 26 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1320
Open AccessA New Frontier for Drug-Coated Balloons: Treatment of “De Novo” Stenosis in Large Vessel Coronary Artery Disease
Background: Drug-coated balloons (DCB) are a well-established option for treating in-stent restenosis endorsed by European Guidelines on myocardial revascularization. However, in recent years, a strategy of “leaving nothing behind” with DCB in de novo coronary stenosis has emerged as an appealing approach. Methods: We performed a systematic review to evaluate the current literature on the use of drug-coated balloons in the treatment of de novo stenosis in large vessel disease. Results: Observational studies, as well as randomized studies, demonstrated the safety of DCB percutaneous coronary interventions (PCI) in large vessel disease. The rate of major adverse cardiac events is even lower compared to drug-eluting stents in stable coronary artery disease. Conclusions: DCB PCI is feasible in large vessel disease, and future large, randomized studies are ongoing to confirm these results.
- Open Access
- 1 December 2021
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 23 (Supplement)
695 Upregulated monocyte expression of PLIN2 is associated with plaque instability in coronary artery disease
Perilipin 2 (PLIN2), a protein associated with intracellular lipid droplets (LDs), is involved in lipid metabolism of macrophages resident in atherosclerotic plaques and its up-regulation leads to LDs accumulation. LDs enlargement results in the macrophage transformation into foam cells, a key step for the onset of atherosclerosis. In the present study, we investigated the role of PLIN2 and its regulation mechanisms in atherosclerosis and plaque instability in patients with a diagnosis of ST-elevation myocardial infarction (STEMI) and stable chronic angina (SA). We enrolled 120 patients with a diagnosis of STEMI and 42 SA patients with symptoms of stable effort angina lasting more than 12 months. Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA whole blood samples through standard gradient centrifugation over Ficoll-Hypaque. Monocytes were purified through indirect magnetic labelling of PBMCs. PLIN2 mRNA expression was investigated by Real Time-PCR and PLIN2 protein level was analysed in CD14+ monocytes by flow cytometry. Proteasome activity was assayed using AMC-tagged peptide substrate (Succ-LLVY-AMC), which releases free highly fluorescent AMC (Ex/Em 350/440 nm) in the presence of proteolytic activity. In CD14+ monocyte, PLIN2 protein expression was significantly increased in STEMI as compared to SA patients (P < 0.001), while PLIN2 mRNA level was not different in the two groups (P = n.s.). Despite proteasome activity was higher in STEMI as compared to SA patients (P < 0.001), significant inverse correlations were evident between PLIN2 levels and proteasome activity in the two groups (P = 0.05). CD14+ monocyte PLIN2 protein expression was higher in STEMI as compared to SA patients suggesting an involvement in plaque instability. Despite proteasome activity was higher in STEMI patients, probably due to the elevated inflammatory burden, PLIN2 could escape proteasome degradation in a more efficient manner in STEMI as compared to SA patients.
- 1 December 2021
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 23 (Supplement)
Open Access695 Upregulated monocyte expression of PLIN2 is associated with plaque instability in coronary artery disease
Perilipin 2 (PLIN2), a protein associated with intracellular lipid droplets (LDs), is involved in lipid metabolism of macrophages resident in atherosclerotic plaques and its up-regulation leads to LDs accumulation. LDs enlargement results in the macrophage transformation into foam cells, a key step for the onset of atherosclerosis. In the present study, we investigated the role of PLIN2 and its regulation mechanisms in atherosclerosis and plaque instability in patients with a diagnosis of ST-elevation myocardial infarction (STEMI) and stable chronic angina (SA). We enrolled 120 patients with a diagnosis of STEMI and 42 SA patients with symptoms of stable effort angina lasting more than 12 months. Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA whole blood samples through standard gradient centrifugation over Ficoll-Hypaque. Monocytes were purified through indirect magnetic labelling of PBMCs. PLIN2 mRNA expression was investigated by Real Time-PCR and PLIN2 protein level was analysed in CD14+ monocytes by flow cytometry. Proteasome activity was assayed using AMC-tagged peptide substrate (Succ-LLVY-AMC), which releases free highly fluorescent AMC (Ex/Em 350/440 nm) in the presence of proteolytic activity. In CD14+ monocyte, PLIN2 protein expression was significantly increased in STEMI as compared to SA patients (P < 0.001), while PLIN2 mRNA level was not different in the two groups (P = n.s.). Despite proteasome activity was higher in STEMI as compared to SA patients (P < 0.001), significant inverse correlations were evident between PLIN2 levels and proteasome activity in the two groups (P = 0.05). CD14+ monocyte PLIN2 protein expression was higher in STEMI as compared to SA patients suggesting an involvement in plaque instability. Despite proteasome activity was higher in STEMI patients, probably due to the elevated inflammatory burden, PLIN2 could escape proteasome degradation in a more efficient manner in STEMI as compared to SA patients.
- Open Access
- 2 October 2020
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 10 (6) , 633-642
Role of perilipin 2 in microvascular obstruction in patients with ST-elevation myocardial infarction
Coronary microvascular obstruction (MVO) occurs frequently in patients with ST-elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). However, mechanisms are multiple and not yet fully understood. Perilipin 2 (PLIN2) is involved in lipid metabolism of macrophages resident in atherosclerotic plaques, along with a role in enhancing plaque inflammation. We studied the association between PLIN2 and MVO in STEMI patients undergoing primary PCI, and we assessed the role of PLIN2 to predict major adverse cardiovascular events (MACEs). STEMI patients undergoing primary PCI were enrolled. PLIN2 was evaluated in peripheral blood monocytes; MVO was assessed using coronary angiogram. MACEs, as a composite of cardiac death, non-fatal myocardial infarction, re-admission for heart failure, and target vessel revascularization were investigated at follow-up. Among 100 STEMI patients, 33 (33.0%) had MVO. Patients with MVO had higher levels of PLIN2 (1.03 ± 0.28 vs. 0.90 ± 0.16, P = 0.019). Age [odds ratio (OR) (95% confidence interval, CI), 1.045 (1.005–1.087), P = 0.026] and PLIN2 [OR (95% CI), 16.606 (2.027–136.030), P = 0.009] were associated with MVO at univariate analysis, although only PLIN2 [OR (95% CI), 12.325 (1.446–105.039), P = 0.022] was associated with MVO at multivariate analysis. After a mean follow-up of 182.2 ± 126.6 days, 13 MACEs occurred. MVO [hazard ratio (HR) (95% CI), 6.791 (2.053–22.462), P = 0.002], hypercholesterolaemia [HR (95% CI), 3.563 (1.094–11.599), P = 0.035], and PLIN2 [HR (95% CI), 82.991 (9.857–698.746), P < 0.001] were predictors of MACEs at univariate analysis, although only PLIN2 [HR (95% CI), 26.904 (2.461–294.100), P = 0.007] predicted MACEs at multivariate analysis. In STEMI patients undergoing primary PCI, PLIN2 was independently associated with MVO and was an independent predictor of MACEs at follow-up, suggesting to further explore PLIN2 as a target for future cardioprotection therapies.
- 2 October 2020
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 10 (6) , 633-642
Open AccessRole of perilipin 2 in microvascular obstruction in patients with ST-elevation myocardial infarction
Coronary microvascular obstruction (MVO) occurs frequently in patients with ST-elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). However, mechanisms are multiple and not yet fully understood. Perilipin 2 (PLIN2) is involved in lipid metabolism of macrophages resident in atherosclerotic plaques, along with a role in enhancing plaque inflammation. We studied the association between PLIN2 and MVO in STEMI patients undergoing primary PCI, and we assessed the role of PLIN2 to predict major adverse cardiovascular events (MACEs). STEMI patients undergoing primary PCI were enrolled. PLIN2 was evaluated in peripheral blood monocytes; MVO was assessed using coronary angiogram. MACEs, as a composite of cardiac death, non-fatal myocardial infarction, re-admission for heart failure, and target vessel revascularization were investigated at follow-up. Among 100 STEMI patients, 33 (33.0%) had MVO. Patients with MVO had higher levels of PLIN2 (1.03 ± 0.28 vs. 0.90 ± 0.16, P = 0.019). Age [odds ratio (OR) (95% confidence interval, CI), 1.045 (1.005–1.087), P = 0.026] and PLIN2 [OR (95% CI), 16.606 (2.027–136.030), P = 0.009] were associated with MVO at univariate analysis, although only PLIN2 [OR (95% CI), 12.325 (1.446–105.039), P = 0.022] was associated with MVO at multivariate analysis. After a mean follow-up of 182.2 ± 126.6 days, 13 MACEs occurred. MVO [hazard ratio (HR) (95% CI), 6.791 (2.053–22.462), P = 0.002], hypercholesterolaemia [HR (95% CI), 3.563 (1.094–11.599), P = 0.035], and PLIN2 [HR (95% CI), 82.991 (9.857–698.746), P < 0.001] were predictors of MACEs at univariate analysis, although only PLIN2 [HR (95% CI), 26.904 (2.461–294.100), P = 0.007] predicted MACEs at multivariate analysis. In STEMI patients undergoing primary PCI, PLIN2 was independently associated with MVO and was an independent predictor of MACEs at follow-up, suggesting to further explore PLIN2 as a target for future cardioprotection therapies.